RU2362578C1 - Medicinal preparation for treatment of diabetes and method of its preparation - Google Patents

Abstract

FIELD: medicine. ^ SUBSTANCE: medicinal preparation for diabetes treatment contains active pharmaceutical ingredients, obtained from root of rehmania (Radix Rehmanniae), root of astragalus (Radix Astragali), rhizomes of yam (Rhizoma Dioscoreae), root of kudzu hemp (Radix Puerariae Lobatae), root of snake gourd (Radix Trichosanthis), baculums with stigmas of corn (Stylus Zeae Maydis), fruits of schizandra (Fructus Schisandrae Sphenantherae) and Glibenclamidum (Glibenclamide), taken in a certain parity. Way of preparation of a medicinal preparation in the form of drop-pills. A way of preparation of a medicinal preparation in the form of pills. A way of preparation of a medicinal preparation in the form of capsules. A way of preparation of a medicinal preparation in the form of tablets. A way of preparation of a medicinal preparation in the form of granules. A way of preparation of a medicinal preparation in the form of soft capsules. A way of preparation of a medicinal preparation in the form of a powder. ^ EFFECT: efficiency for diabetes treatment. ^ 14 cl, 3 tbl, 18 ex

Description

FIELD OF TECHNOLOGY

This invention relates to drugs, in particular to a formula combining Chinese and Western medicine, for the treatment of diabetes.

BACKGROUND OF THE INVENTION

In traditional Chinese medicine, diabetes mellitus (diabetes) is also called Xiao Ke disease. It is an endocrine metabolic disease and is characterized by hyperglycemia as a result of absolute or relative insulin deficiency. The main clinical symptoms are polydipsia, polyphagia, polyuria and cachexia. In diabetes, mortality and morbidity with diseases such as heart disease, stroke, blindness are 2-5 times higher than non-diabetics, ulcers of the lower extremities and the percentage of amputations are 20 times higher than non-diabetics.

In developed countries, diabetes ranks third among noncommunicable diseases after cardiovascular disease and neoplasm / cancer and has become a global problem that threatens human health.

Studies have shown that the number of people with diabetes in the world was 120 million in 1994, 135 million in 1997, 175 million in 2000. It is estimated that in 2010 the number of cases will reach 239 million. In developing countries, incidence increased by 200%. China, India and some developing countries in Africa are the main regions of the incidence. Hospitals and the market - both require highly effective diabetes care products.

Currently, diabetes is in most cases treated with chemosynthesis, which brings a satisfactory short-term effect, but a rather weak effect with prolonged treatment, and has side effects and complications.

Chinese Patent Application No. CN 1562188A, published January 12, 2005, describes a preparation for treating Xiao Ke disease (diabetes) consisting of 4,000 grams of Radix Puerariae root, 240 grams of Remix root (Radix Rehmanniae), 80 grams of root Astragalus (Radix Astragali), 400 grams of root of Trihozanthes (Radix Trichosanthis), 400 grams of columns with stigmas of corn (Stylus Zeae Maydis), 80 grams of fruits of Schisandra chinensis (Fructus Schisandrae Sphenantherae), 40 grams of rhizome Diocorea (Rhizome Diheoresci (Glibenclamide). In this formula, Pueraria root is the main drug and amounts to 4000 parts of the weight, while the rest of the drugs make up only 1240 parts of the weight. The dosage of Pueraria root is much higher than the dosage of the remaining components in the formula and the standard clinical dosage in the Chinese Pharmacopoeia, which damages the effect of other drugs in the formula. The composition of this formula is obviously unreasonable. In addition, according to conventional manufacturing methods, with a larger amount of Pueraria root for extraction, the proportion of the obtained liquid extract is large, so the dosage of this drug is large and inconvenient to use.

SUMMARY OF THE INVENTION

The aim of the invention is the creation of a new drug that takes into account various traditional Chinese medicine to increase its effectiveness.

To achieve the above objectives, this invention provides a medicament for the treatment of diabetes, the active pharmaceutical ingredients of which are obtained from the following starting materials:

600-1200 parts of the weight of the root of Remannia (Radix Rehmanniae), 200-400 parts of the weight of the root of Astragalus (Radix Astragali), 100-200 parts of the weight of the rhizome of Dioscorea (Rhizoma Dioscoreae), 1000-2000 parts of the weight of the root of Pueraria lobed (Radix Puerariae Lobatae), 1000-2000 parts by weight of the root Trichosanthis (Radix Trichosanthis), 1000-2000 parts by weight of the columns with stigmas of corn (Stylus Zeae Maydis), 200-400 parts by weight of the fruits of Chinese magnolia vine (Fructus Schisandrae Sphenantherae) and 0.2-1.5 parts by weight of Glibenclamide .

Preferably, the active pharmaceutical ingredients of the drug are derived from the following starting materials:

600-900 parts of the weight of the root of Remannia, 200-300 parts of the weight of the root of Astragalus, 100-150 parts of the weight of the rhizome of Dioscorea, 1000-1500 parts of the weight of the root of Pueraria lobed, 1000-1500 parts of the weight of the root of Trichozanthes, 1000-1500 parts of the weight of the columns with stigmas of corn , 200-300 parts by weight of the fruits of Chinese magnolia vine and 0.2-1.0 parts by weight of Glibenclamide.

Even more preferably, the active pharmaceutical ingredients of the drug are derived from the following starting materials:

636 parts of the weight of the root of Remannia, 212 parts of the weight of the root of Astragalus, 106 parts of the weight of the rhizome of Dioscorea, 1060 parts of the weight of the root of Pueraria lobed, 1060 parts of the weight of the root of Trihozanthes, 1060 parts of the weight of the stalks of corn, 212 parts of the weight of the fruits of Chinese magnolia vine and 1 part of the weight of Glibenclamide .

The drug of the present invention is based on the formulas of Yu quan San and Xiao Ke Fang, owned by the well-known Dr. Ye Tianshi of the Qing Dynasty, which have been modified to support the kidneys, support forces (increase tone) and increase body fluid production. In the formula, Remannia root serves to nourish the kidneys, Astragalus root to support strength (increase tone), increase body fluid production and quench thirst, these two drugs play a major role in the formula; Dioscorea rhizome serves to improve the functioning of the lungs and spleen, support the lungs and kidneys, and together with the root of Remannia for nutrition of Yin and for the treatment of kidneys; Pueraria root serves to increase Yang energy and increase body fluid production; with Astragalus root help to improve spleen function, deliver essences to the lungs, these two drugs play an important role in the formula; Trihozanthes root is used to clean the pathogenic stomach, to nourish the stomach, moisturize the lungs, reduce excitement and increased thirst / polydipsia to an average level. Columns with stigmas of corn are used for diuresis to relieve swelling, coordinate kidney function, these two drugs play an auxiliary role in the formula; the fruits of Chinese magnolia vine serve to support the lungs at the top, to strengthen the kidneys and increase the production of body fluid from below, to calm the psyche inside and reduce perspiration from the outside, play the role of a conductor in the formula. In a complex, the formula serves to power the kidneys, increase energy and increase fluid production. Glibenclamide (Western medicine) is used to relieve symptoms of Xiao Ke disease and reduce blood sugar.

All active pharmaceutical constituents in a medicament in accordance with the present invention are based on the theory of traditional Chinese medicine and practical experience. The formula consists of well-selected substances in the correct proportion, and the effect of it is much better than the drug described in Chinese patent application No. CN 1562188A, and Glibenclamide. Thus, the purpose of this invention is to provide diabetes patients with a safer and more effective drug - achieved.

According to pharmaceutical requirements, the formula can be prepared in various forms for clinical use, including in the form of droplets, pills, tablets, capsules, soluble granules, soft-capsule capsules and powder.

The process of preparing the above forms

I Preparing Drops

Pueraria root, lobed, Remannia root, stigmas of corn, Trichozanthes root, Astragalus root, fruits of Chinese magnolia vine and rhizome Dioscorea are infused with water, then filtered, and the filtrate is concentrated (evaporated) to a moderate amount (on a moderate scale) and placed on cooling. Ethanol is added to the filtrate to make a solution containing 60% ethanol, and this solution settles for 24 hours and then filtered, the filtrate is evaporated (concentrated) to get rid of the smell of ethanol. Two parts of water are added to the concentrate, and all this shakes off until completely dissolved. Next, the solution is placed in the prepared large-pore resin and the resin is eluted with water until the eluent is discolored. Then the resin is eluted with 70% ethanol, the eluent is collected until it is colorless, and concentrated in the extract. A moderate amount of Polyethylene Glycol 6000 (Polyethylene Glycol 6000 (PEG-6000) and stearic acid (stearic acid) is placed in a container and heated to 100-110 ° until the mixture is completely dissolved, after which Glibenclamide and the above extract are added. After uniform dissolution are made tablet drops / pills by using liquid paraffin as a cooling agent, then the tablet drops are removed and dried from the paraffin base.

II Preparation of pills

Method 1: Remannia root, Pueraria root lobate, Trichozanthes root and corn stigmas are infused with water for 5 hours, then filtered, and the filtrate is concentrated (evaporated) on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, the fine powder is ground in water (water), then dried, after which Glibenclamide is added, the pills are obtained using black iron oxide (black ferric oxide), talcum powder (talcum powder) and a binding agent as a coating substance, then the coating is polished and then dried.

Method 2: Remannia root, Pueraria root lobate, Trichozanthes root and stigmas with corn stalks infused with water for 5 hours, then filtered and concentrated (evaporated) on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the powder mixes well with a liquid concentrate, then it is dried and ground into a fine powder; the pills are made using a pill making machine and then dried, Glibenclamide is added, the pills are made using black iron oxide, talc powder and a binder as a coating agent, then the coating is polished and then dried.

Method 3: Remannia root, Pueraria root lobate, Trihozanthes root and corn stigmas infused with water for 5 hours, filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the powder mixes well with a liquid concentrate, then it is dried and ground into a fine powder; granules are made in a single-stage granulator, Glibenclamide is added, and the pills are obtained by compression.

Method 4: Remannia root, Pueraria root lobate, Trihozanthes root and stalks of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into fine powder; the fine powder is converted into granules in a single-stage granulator with liquid concentrate, Glibenclamide is added, and the pills are made by compression.

III Preparation of capsules

Remannia root, Pueraria root lobate, Trihozanthes root and corn stigmas are infused with water for 5 hours, filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the powder is mixed well with liquid concentrate, then dried and ground into a fine powder, after which Glibenclamide and a moderate amount of dextrin are added and mixed well with the above fine powder for preparation granules, which are then placed in capsules.

IV Preparation of tablets

Remannia root, Pueraria root lobate, Trihozanthes root and corn stigmas are infused with water for 5 hours, filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the powder is mixed well with a liquid concentrate, then dried and ground into a fine powder, after which Glibenclamide and a moderate amount of dextrin are added and mixed well with the above fine powder to prepare granules that then dried and mixed with 0.5% magnesium stearate for compression into tablets.

V Preparation of soluble granules

Remannia root, Pueraria root lobate, Trihozanthes root and corn stigmas are infused with water for 5 hours, filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, which is then mixed well with a liquid concentrate, dried and ground into a fine powder; Glibenclamide and a moderate amount of dextrin are added to the fine powder, mix well to obtain granules.

VI Preparation of soft capsules / capsules in a soft shell

Remannia root, Pueraria root lobate, Trihozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the powder mixes well with a liquid concentrate, then it is dried and ground into a fine powder; after which Glibenclamide is added and mixed well with fine powder, then the same amount of Polyethylene Glycol-400 (Poly ethylene Glycol-400) and a small amount of glycerin are added, mix well and are pressed into soft capsules.

VII Preparation of powder

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the powder mixes well with a liquid concentrate, then it is dried and ground into a fine powder; after which Glibenclamide is added and mixed well with the fine powder to obtain the final powder.

The medicine related to this invention has reliable manufacturing methods and is controlled in proportions. Technical research is as follows.

1. Materials and methods

1.1. Materials

"The drug (medicine) Xiao Ke" here is manufactured according to method 4 of Chinese patent application No. CN 1562188A.

A “preparation (medication) of the present invention” is made here with reference to method 1 of the present invention.

1.2. Methods

1.2.1

1.2.2 The remaining ingredients relate to the applications of the Pharmacopoeia of China (2000 items).

2. Data

Ingredient Xiao Ke drug The preparation of this invention The resulting proportion of extract 25 ~ 30% 15 ~ 18% Pills External signs flat round, flat, uniform color Decay / Assimilation Time 107 min <80 min Capsules Content Character Easy to bind to column Homogeneous granules Decay / Assimilation Time 30 minutes <20 min Pills Decay / Assimilation Time 64 min <50 min

Conclusion:

The above experiments show that the composition of the drug (s) of the present invention is more rational, technologically stable, finer dosed and the quality of the final product is stable and controlled. Compared with existing technology, the preparation of the present invention has high stability; the final product has good cleavage and homogeneity.

The effect of the drug of the present invention is demonstrated through the following pharmacodynamic experiments in animals.

1. Materials and methods

1.1 Materials

1.1.1 Medicines and reagents

The “Xiao Ke drug” (powder) in this case is made according to method 4 of Chinese patent application No. CN 1562188A, while the preparation of the present invention (in this case, powder) is made according to method 1 of the present invention. Before the experiment, the powders were diluted with water to a certain concentration.

Glibenclamide: Products of the Tianjin Drugs Institute, China.

Streptozotcin (Streptozotcin): products of Sigma (Sigma), USA.

Standard glucose solution: products of the Shanghai Institute of Biological Products.

Glucoseoxidase (Glucoseoxidase): from the Guangdong Local Clinical Testing Center (Guangdong Provincial Clinical Test Center).

Standard cholesterol solution (cholesterol): products of the Beijing Chemical Industry Factory (Beijing Chemical Industry Factory).

Triacylglycerol Test Box (import): Packed at Shanghai Changzheng Medical Science Co. (Shanghai Changzheng Medical Science Co.).

High-fat emulsion preparation: 5 gram cholesterol (import from Holland), deoxysodium cholate (0.3 g) (Serva products of the USA), pork fat 20 grams (purchased at the store), half a dose of polyoxyethylene fatty acid ester (polysorbate) 80 (import from Japan) and a half dose of 1, 2 propylene glycol (products of the First Reagent Factory of Shanghai) for the preparation of 50 ml of emulsion.

1.1.2 Basic tools: BBO type fully automatic biochemical apparatus for analysis (products from Kangning (Kangning Co.) USA).

1.1.3 Animals: NIH mice and SD rats (supplied by Guangdong Experimental Animal Farm for experiments).

1.2 Methods

1.2.1 Effects on the blood sugar level of a normal mouse

40 healthy mice (half male, half female) weighing 23-25 grams were randomly assigned to 4 groups (10 mice in each group). The usual group of control experimental animals was injected with an equal amount of normal saline solution intragastrically; a positive group of control experimental animals were given glibenclamide (2 mg / kg) intragastrically; the group of control experimental animals “Xiao Ke drug (UPC)” was given the drug Xiao Ke intragastrically, which is equivalent to 34.94 g / kg of medicinal raw material and contains 2 mg of Glibenclamide; the group representing the “preparation of the present invention” was given the preparation according to the present invention intragastrically, which is equivalent to 8.64 g / kg of the medicinal raw material and contains 2 mg of glibenclamide. The mice were fed normally for 3 days, then starved for 12 hours, and blood was drawn from the eyeball. The blood sugar level was determined by the glucose oxidase test (glucoseoxidase test) and was taken as the base blood sugar level. Then, the mice were individually given the preparations intragastrically 3 and 7 hours after taking the medications; the blood sugar level was individually determined. The baseline blood sugar value minus the blood sugar level after taking medication is a characteristic of lowering blood sugar.

1.2.2 Effect of streptozotcin on the blood sugar level of diabetic rats.

Healthy rats (half male, half female) weighing 150-180 grams were fed normally for 5 days, then starved for 12 hours, Streptozotzin (50 mg / 5 ml / kg, prepared with a pH value of 4.5 buffer solution was rapidly introduced) citric acid) into a vein in the tail of a rat to establish animal models.

The usual group was injected with an equal amount of buffer solution. After 2 weeks, blood sugar levels were determined, and rats whose sugar level exceeded 16.8 mmol / L and urinary glucose was constantly +++ were selected as rats satisfying the requirements (UT). Rats that met the requirements (UT) were randomly assigned to 4 groups. The usual group of control experimental animals was also determined. The drugs were given individually intragastrically once a day for 4 weeks. The normal and reference groups received an equal amount of normal saline solution intragastrically. A positive group of control experimental animals was given glibenclamide (1 mg / kg) intragastrically. The group of control experimental animals "Xiao Ke drug (SCR)" was given medicine Xiao Ke intragastrically, which is equivalent to 17.47 g / kg of medicinal raw material and contains 1 mg of Glibenclamide; the group representing the preparation of the present invention was given the preparation of the present invention intragastrically, which is equivalent to 4.32 g / kg of the medicinal raw material and contains 1 mg of Glibenclamide. After stopping the medication, the blood sugar level was measured the next day using the glucose oxidase test (glycoseoxidase test) to compare the differences between different groups.

1.2.3 Effects on cholesterol, triacylglycerols, liver function, renal function and blood rheology in diabetic rats complicated by hyperlipemia (hyperlipemia).

The method for determining the diabetic rat model caused by streptozotocin is the same as in experiment 1.2.2. 40 selected rats were randomly divided into 4 groups, the usual group of control experimental animals was also determined. The drugs were given individually intragastrically once a day for 4 weeks. The normal and reference groups received an equal amount of normal saline solution intragastrically. A positive group of control experimental animals was given glibenclamide (1 mg / kg) intragastrically. The group of control experimental animals "Xiao Ke drug (UPC)" was given the drug Xiao Ke intragastrically, which is equivalent to 17.47 g / kg of medicinal raw material and contains 1 mg of Glibenclamide; the group representing the “preparation of the present invention” was given the preparation presented in the present invention intragastrically, which is equivalent to 4.32 g / kg of medicinal raw material and contains 1 mg of Glibenclamide. The preparations were given individually in the morning, and 5 ml / kg of high-fat emulsion was given individually in the afternoon continuously for 3 weeks. After stopping the medication and 12-hour fasting, light anesthesia was introduced with ether and blood samples were taken from the heart to determine cholesterol (using the sulfate color test) and triacylglycerol (using the zymologic method-GPO )

и различия между группами анализировались с помощью т-теста/проверка по критерию Стьюдента (t-test).1.3 Statistics are displayed as

and differences between groups were analyzed using a t-test / student test (t-test).

2. Results

2.1 Effect on the blood sugar level of a normal mouse (see table 1).

Table 1

±s, n=10)Effects on the blood sugar level of a normal mouse (

± s, n = 10) Group Dosage Baseline sugar Decrease in sugar level after treatment (mmol / l) d) (g / k in the blood (mmol / l) 3 hours after treatment 7 hours after treatment Control - 4.70 ± 0.90 1.37 ± 0.93 0.99 ± 1.17 Glibenclamide 2 × 10-3 5.26 ± 1.59 2.07 ± 0.46 * 3.23 ± 1.57 ** Xiao Ke a drug 34.94 4.83 ± 1.23 2.12 ± 0.63 * 3.17 ± 1.67 ** Drug from of the present inventions 8.64 5.14 ± 1.52 2.25 ± 0.42 * 3.43 ± 1.55 **

Note: comparison with the control group: * P <0.05; ** P <0.01 (copy)

2.2 Effect of Streptozotcin-initiated diabetic rat blood sugar (see table 2).

table 2

±s, n=10)The effect on the blood sugar level of diabetic rats initiated by streptozotcin (

± s, n = 10)

Group Dosage (g / kg) Sugar level
in blood (mmol / l) Before treatment Reduction after treatment Normal - 5.56 ± 0.95 0.25 ± 0.11 Control (model) - 24.23 ± 3.94 -1.52 ± 4.69 Glibenclamide 1 × 10 ^-3 25.64 ± 3.47 2.90 ± 3.02 * Xiao Ke a drug 17.47 25.19 ± 2.98 3.05 ± 1.90 * The preparation of the present invention 4.32 24.69 ± 3.73 3.66 ± 2.57 **

2.3 Effects on cholesterol, triacylglycerol, liver function, kidney function and blood rheology in diabetic rats complicated by hyperlipidemia (see table 3).

Table 3

±s, n=10)Effects on cholesterol, triacylglycerol, liver function, kidney function and blood rheology in diabetic rats complicated by hyperlipidemia (

± s, n = 10) Group Dosage (g / kg) Total serum cholesterol (mmol / L) (serum total cholesterol mmol / L) Serum triacylglycerol (MMon / n) (serum triacylglycerol mmol / L) Plain - 0.60 ± 0.28 1.48 ± 0.49 Control (model) - 1.59 ± 0.51 2.96 ± 1.45 Glibenclamide 1 × 10 ^-3 1.44 ± 0.43 2.52 ± 1.12 Xiao Ke drug 17.47 1.25 ± 0.33 1.95 ± 0.71 Drug from 4.32 0.96 ± 0.21 ** 1.58 ± 0.71 * of the present inventions

Note: comparison with the Glibenclamide group and the “Xiao Ke drug” group: * P <0.05; ** P <0.01.

Conclusion: 1.

1. Experiments have shown that the Glibenclamide group, the Xiao Ke drug group, and the Drug of the present invention group all have the effect of lowering blood sugar in ordinary mice and rats of diabetics initiated by Streptozotocin (DRIS), compared to the control group, P <0.05 or P <0.01. But there is no noticeable difference in effect between the three groups. The preparation of the present invention has an undeniable effect that inhibits the growth of total serum cholesterol and triacylglycerol in diabetic rats complicated by hyperlipidemia compared with the control group, the Glibenclamide group, the Xiao Ke drug group, P <0.05 or P <0.01. Glibenclamide and Xiao Ke do not have this effect. This suggests that the effect of the drug of the present invention is superior to the effect of Xiao Ke and Glibenclamide.

2. The invented preparation consists of carefully selected materials with the correct proportions based on theories of traditional Chinese medicine and practical experience of use, the effect of it is clearly superior to the drug Xiao Ke and Glibenclamide. The dosage is noticeably lower than that of Xiao Ke, which makes it more convenient to carry with you. As a result, the drug presented in the present invention is safe and effective in the treatment of diabetes.

DETAILED DESCRIPTION OF THE INVENTION

Implementation Method 1: Pill Production

The amount of active pharmaceutical starting materials and Glibenclamide is determined in the following proportions: Remannia root: 636 parts by weight; Astragalus root: 212 parts of weight; Dioscorea rhizome: 106 parts in weight; Pueraria root lobed: 1060 parts by weight; Trichozanthes root: 1060 parts of weight; stigmas of corn: 1060 parts by weight; fruits of Chinese magnolia vine: 212 parts of weight and Glibenclamide: 1 part of weight.

Remannia root, Pueraria lobate root, Trihozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated to a moderate amount so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorean rhizome are ground into a large powder and mixed well with liquid concentrate, then dried and ground into a fine powder and mixed well; the fine powder is ground with water (in water), then it is dried, after which iron oxide, talc powder, a moderate amount of a binding agent and glibenclamide are added, the pills are obtained after polishing the coating of the pills.

Implementation Method 2: Production of Pills

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions: Remannia root: 600 parts by weight; Astragalus root: 200 parts of weight; Dioscorea rhizome: 100 parts in weight; Pueraria root lobed: 1000 parts of weight; Trichozanthes root: 1000 parts of weight; stigmas of corn: 1000 parts by weight; fruits of Chinese magnolia vine: 200 parts by weight; and Glibenclamide: 1.5 frequent. weight.

Remannia root, Pueraria root lobate, Trihozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated (evaporated) on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mix well with a liquid concentrate, then ground into a fine powder and mix well; the fine powder is ground in water (water), then it is dried, after which iron oxide, talc powder and a moderate amount of a binding agent and glibenclamide are added, the pills are obtained by polishing the coating of the pills.

Implementation Method 3: Production of Capsules

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions: Remannia root: 636 parts by weight; Astragalus root: 212 parts of weight; Dioscorea rhizome: 106 parts in weight; Pueraria root lobed: 1060 parts by weight; Trichozanthes root: 1060 parts of weight; stigmas of corn: 1060 parts by weight; fruits of Chinese magnolia vine: 212 parts of weight and Glibenclamide: 1 part of weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide and a moderate amount of dextrin are added and well mixed to prepare granules, which are then filled into capsules.

Implementation Method 4: Production of Capsules

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions: Remannia root: 1200 parts by weight; Astragalus root: 400 parts of weight; Dioscorea rhizome: 200 parts of weight; Pueraria root lobed: 2000 parts of weight; Trichozanthes root: 2000 parts of weight; stigmas of corn: 2000 parts of weight; Chinese magnolia vine fruits: 400 parts by weight; and Glibenclamide: 0.2 parts by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, then Glibenclamide and a moderate amount of dextrin are added and mixed well to prepare granules, which are then filled into capsules.

Implementation Method 5: Tablet Production

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 636 parts of weight; Astragalus root: 212 parts of weight; Dioscorea rhizome: 106 parts in weight; Pueraria root lobed: 1060 parts by weight; Trichozanthes root: 1060 parts of weight; stigmas of corn: 1060 parts by weight; fruits of Chinese magnolia vine: 212 parts of weight and Glibenclamide: 1 part of weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide and a moderate amount of dextrin are added to the fine powder and mixed well to prepare granules, the granules are dried and mixed with 0.5 % magnesium stearate (magnesium stearate), and then pressed into tablets.

Implementation Method 6: Tablet Production

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 1200 parts of weight; Astragalus root: 400 parts of weight; Dioscorea rhizome: 200 parts of weight; Pueraria root lobed: 2000 parts of weight; Trichozanthes root: 2000 parts of weight; stigmas of corn: 2000 parts of weight; Chinese magnolia vine fruits: 400 parts by weight; and Glibenclamide: 1.5 parts by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide and a moderate amount of dextrin are added to the fine powder and mixed well to prepare granules, the granules are dried and mixed with 0.5 % magnesium stearate, and then pressed into tablets.

Implementation Method 7: Production of soluble granules

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 600 parts of weight; Astragalus root: 200 parts of weight; Dioscorea rhizome: 100 parts in weight; Pueraria root lobed: 1000 parts of weight; Trichozanthes root: 1000 parts of weight; stigmas of corn: 1000 parts by weight; Chinese magnolia vine fruits: 200 parts by weight; and Glibenclamide: 0.2 part by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide and a moderate amount of dextrin are added to the fine powder and mixed well to prepare soluble granules.

Implementation Method 8: Production of Soft Capsules / Soft Shells

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 900 parts of weight; Astragalus root: 300 parts of weight; Dioscorea rhizome: 150 parts of weight; Pueraria root lobed: 1,500 parts in weight; Trichozanthes root: 1,500 parts of weight; stigmas of corn: 1,500 parts of weight; Chinese magnolia vine fruits: 300 parts by weight; and Glibenclamide: 0.2 parts by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide is added to the fine powder and mixed well, after which the same amount of Polyethylene glycol 400 and a small amount of glycerin are added, mixes well and is pressed into soft-shell capsules.

Implementation Method 9: Powder Production

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 900 parts of weight; Astragalus root: 300 parts of weight; Dioscorea rhizome: 150 parts of weight; Pueraria root lobed: 1,500 parts in weight; Trichozanthes root: 1,500 parts of weight; stigmas of corn: 1,500 parts of weight; Chinese magnolia vine fruits: 300 parts by weight; and Glibenclamide: 1 part by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, then Glibenclamide is added and mixed well, from this we obtain the necessary powder.

Implementation Method 10: Production of Pills

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 600 parts of weight; Astragalus root: 200 parts of weight; Dioscorea rhizome: 100 parts in weight; Pueraria root lobed: 1000 parts of weight; Trichozanthes root: 1000 parts of weight; stigmas of corn: 1000 parts by weight; Chinese magnolia vine fruits: 200 parts by weight; and Glibenclamide: 1 part by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder; the fine powder is ground in water (water), then dried, after which iron oxide, talc powder and a moderate amount of a binding agent and glibenclamide are added, the pills are obtained after polishing the coating of the pills and drying.

Implementation Method 11: Production of Pills

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 900 parts of weight; Astragalus root: 200 parts of weight; Dioscorea rhizome: 130 parts of weight; Pueraria root lobed: 1100 parts of weight; Trichozanthes root: 1200 parts of weight; stigmas of corn: 1300 parts of weight; Chinese magnolia vine fruits: 250 parts by weight; and Glibenclamide: 0.5 parts by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder; the fine powder is ground in water (water), then dried, after which iron oxide, talc powder and a moderate amount of a binding agent and Glibenclamide are added, the pills are obtained after polishing the coating of the pills and drying.

Implementation Method 12: Production of Pills

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 750 parts of weight; Astragalus root: 250 parts of weight; Dioscorea rhizome: 130 parts of weight; Pueraria lobate root: 1300 parts of weight; Trichozanthes root: 1300 parts of weight; stigmas of corn: 1300 parts of weight; Chinese magnolia vine fruits: 250 parts by weight; and Glibenclamide: 0.5 parts by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder; the fine powder is ground in water (water), then dried, after which iron oxide, talc powder and a moderate amount of a binding agent and Glibenclamide are added, the pills are obtained after polishing the coating of the pills and drying.

Implementation Method 13: Tablet Production

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remanian root 1000 parts by weight, Astragalus root 220 parts by weight, Dioscorea rhizome 110 parts by weight, Pueraria lobate root 1000 parts by weight, Trihozanthes root 1700 parts by weight, corn stalks 1500 parts by weight, Chinese magnolia vine fruits 205 parts by weight and Glibenclamide 0.4 parts by weight .

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide and a moderate amount of dextrin are added to the fine powder and mixed well to prepare granules, which are then dried and mixed well with 0.5% magnesium stearate and pressed into tablets.

Implementation Method 14: Production of Soluble Granules

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 650 parts of weight; Astragalus root: 205 parts of weight; Dioscorea rhizome: 120 parts of weight; Pueraria root lobed: 1700 parts of weight; Trichozanthes root: 1,500 parts of weight; stalks of corn: 1100 parts of weight; Chinese magnolia vine fruits: 220 parts by weight; and Glibenclamide: 0.8 parts by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide and a moderate amount of dextrin are added to the fine powder and mixed well to prepare soluble granules.

Implementation Method 15: Production of Soft Capsules (Soft Shell)

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 950 parts of weight; Astragalus root: 350 parts of weight; Dioscorea rhizome: 180 parts of weight; Pueraria root lobed: 1,500 parts in weight; Trichozanthes root: 1100 parts of weight; stigmas of corn: 1200 parts of weight; Chinese magnolia vine fruits: 280 parts by weight; and Glibenclamide: 1.2 parts by weight.

Remannia root, Pueraria lobate, Trichozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide is added to the fine powder and mixed well, after which the same amount of Polyethylene glycol 400 and a small amount of glycerin are added, mixes well and is pressed into soft-shell capsules.

Implementation Method 16: Production of Powder

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 800 parts of weight; Astragalus root: 210 parts by weight; Dioscorea rhizome: 100 parts by weight; Pueraria root lobed: 1200 parts of weight; Trichozanthes root: 1000 parts of weight; stigmas of corn: 1700 parts of weight; Chinese magnolia vine fruits: 330 parts by weight; and Glibenclamide: 0.9 parts by weight.

Remannia root, Pueraria root lobate, Trihozanthes root and stigmas of corn are infused with water for 5 hours, then filtered, and the filtrate is concentrated (evaporated) on a moderate scale so as to obtain a liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder and mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide is added to the fine powder and mixed well, from this we obtain the necessary powder.

Implementation Method 17: Production of Drops-Pills

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 636 parts of weight; Astragalus root: 212 parts of weight; Dioscorea rhizome: 106 parts in weight; Pueraria root lobed: 1060 parts by weight; Trichozanthes root: 1060 parts of weight; stigmas of corn: 1060 parts by weight; fruits of Chinese magnolia vine: 212 parts of weight and Glibenclamide: 1 part of weight.

Pueraria root, lobed, Remannia root, stigmas of corn, Trihozanthes root, Astragalus root, fruits of Chinese magnolia vine and Dioscorea rhizome are infused with water, then filtered, and the filtrate is concentrated on a moderate scale and placed on cooling. Ethanol is added so that the solution contains 60% ethanol, and this solution settles for 24 hours, after which it is filtered, the filtrate is concentrated to get rid of the smell of ethanol; two parts of water are added to the concentrate and crumbled until completely dissolved. Next, the final solution is placed in the prepared large-pore resin, and the resin is eluted with water until the eluent is discolored. The resin is eluted with 70% ethanol, the eluent is collected until the eluent is decolorized and concentrated in the extract. A moderate amount of Polyethylene Glycol 6000 (PEG-6000) and stearic acid is placed in a container and heated to 100-110 ° C until the mixture is completely dissolved, after which Glibenclamide and the above extract are added. After uniform dissolution, pill drops are formed using liquid paraffin used as a cooler. Drops of pills are obtained after they are removed and dried from paraffin.

Implementation Method 18: Production of Drops-Pills

The amount of pharmaceutical starting materials and Glibenclamide is determined in the following proportions:

Remannia root: 750 parts of weight; Astragalus root: 250 parts of weight; Dioscorea rhizome: 130 parts of weight; Pueraria lobate root: 1300 parts of weight; Trichozanthes root: 1300 parts of weight; stigmas of corn: 1300 parts of weight; Chinese magnolia vine fruits: 250 parts by weight; and Glibenclamide: 0.5 parts by weight.

Pueraria root, lobate, Remannia root, stigmas of corn, Trihozanthes root, Astragalus root, Chinese magnolia vine and Dioscorea rhizome are infused with water, then filtered, and the filtrate is concentrated to regulate the amount and placed on cooling. Ethanol is added so that the solution contains 60% ethanol, and this solution settles for 24 hours, after which it is filtered, the filtrate is concentrated to get rid of the smell of ethanol. Two parts of water are added to the concentrate, and all this shakes off until completely dissolved. Next, the final solution is placed in the prepared large-pore resin, and the resin is eluted with water until the eluent is discolored. The resin is eluted with 70% ethanol. The eluent is collected until discoloration and concentrated in the extract. A moderate amount of Polyethylene Glycol 6000 (PEG-6000) and stearic acid is placed in a container and heated to 100-110 ° C until the mixture is completely dissolved, after which Glibenclamide and the above extract are added and dissolve evenly. Further, after uniform dissolution with liquid paraffin used as a cooler, drop drops are obtained. Drops of pills are obtained after they are removed and dried from paraffin.

Claims (14)

1. A drug for the treatment of diabetes, characterized in that the active pharmaceutical ingredients of the drug are obtained from the following pharmaceutical starting materials:
600-1200 parts of the weight of the root of Remannia (Radix Rehmanniae), 200-400 parts of the weight of the root of Astragalus (Radix Astragali), 100-200 parts of the weight of the rhizome of Dioscorea (Rhizoma Dioscoreae), 1000-2000 parts of the weight of the root of Pueraria lobed (Radix Puerariae Lobatae), 1000-2000 parts by weight of the root Trichosanthis (Radix Trichosanthis), 1000-2000 parts by weight of the columns with stigmas of corn (Stylus Zeae Maydis), 200-400 parts by weight of the fruits of Chinese magnolia vine (Fmctus Schisandrae Sphenantherae) and 0.2-1.5 parts by weight Glibenclamide (Glibenclamide). 2. The drug according to claim 1, characterized in that the active pharmaceutical ingredients of the drug are obtained from the following pharmaceutical starting materials:
600-900 parts of the weight of the root of Remannia, 200-300 parts of the weight of the root of Astragalus, 100-150 parts of the weight of the rhizome of Dioscorea, 1000-1500 parts of the weight of the root of Pueraria lobed, 1000-1500 parts of the weight of the root of Trichozanthes, 1000-1500 parts of the weight of the columns with stigmas of corn , 200-300 parts by weight of the fruits of Chinese magnolia vine and 0.2-1.0 parts by weight of Glibenclamide. 3. The drug according to claim 2, characterized in that the active pharmaceutical ingredients of the drug are obtained from the following pharmaceutical starting materials:
636 parts of the weight of the root of Remannia, 212 parts of the weight of the root of Astragalus, 106 parts of the weight of the rhizome of Dioscorea, 1060 parts of the weight of the root of Pueraria lobed, 1060 parts of the weight of the root Trichozanthes, 1060 parts of the weight of the stalks of corn, 212 parts of the weight of the fruits of Chinese magnolia vine and 1 part of the weight of Glibenclamide . 4. The drug according to claims 1 and 2 or 3, which can be in the form of drops, pills, pills, tablets, capsules, soluble granules, soft capsules or powders. 5. The method of preparation of the drug according to claim 4, containing the following steps: lobed Pueraria root, Remannia root, corn stigmas, Trihozanthes root, Astragalus root, Chinese magnolia vine and Dioscorea rhizomes are infused with water, then filtered and the filtrate is concentrated in moderate scale to obtain a liquid concentrate, and the liquid concentrate is placed on cooling; ethanol is added to the liquid concentrate to create a solution containing 60% ethanol, and this solution is left to stand for 24 hours, filtered and concentrated to obtain an odorless ethanol concentration; two parts of water are added to the concentration and vortexed until completely dissolved; then the final solution is placed in the prepared large-pore resin, and the resin is eluted with water until the eluent decolours, then the resin is eluted with 70% ethanol until the eluent decolours, the eluent is collected and concentrated into the extract; moderate amount of Polyethylene glycol 6000 (Poly ethylene Glycol 6000) and stearic acid are added to the container and heated to 100-110 ° C until completely dissolved, after which Glibenclamide and extract are added and evenly dissolved, then pill drops are made using liquid paraffin as coolers, drop-pills are removed and dried from paraffin. 6. The method of preparation of the drug according to claim 4, comprising the following steps: Remannia root, Pueraria lobate root, Trihosanthes root and corn stigmas infused with water for 5 hours, then filtered and the filtrate was concentrated on a moderate scale so as to obtain liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into fine powder; fine powder is added to the liquid concentrate in order to produce granules in a single-stage granulator, and Glibenclamide is added to the granules, so that they can then be compressed into pills. 7. The method of preparation of the drug according to claim 4, comprising the following steps: Remannia root, Pueraria lobate root, Trihosanthes root and corn stigmas infused with water for 5 hours, then filtered and the filtrate was concentrated on a moderate scale so as to obtain liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the large powder is mixed well with a liquid concentrate, dried and ground into a fine powder; the fine powder is ground in water, then dried, after which Glibenclamide is added, the pills are obtained using black iron oxide, talc powder and a binding agent as a coating agent, then the coating of the pills is polished. 8. The method according to claim 7, where the fine powder is mixed well and converted into pills using a pill manufacturing device, the pills are dried and supplemented with Glibenclamide, the pills are prepared using black iron oxide, talc powder and a binding agent as a coating agent, then polished coating and dried. 9. The method according to claim 7, where the fine powder is mixed well and converted into granules using a single-stage granulator, the granules are supplemented with Glibenclamide and pressed into pills. 10. The method of preparation of the drug according to claim 4, comprising the following steps: Remannia root, Pueraria lobate root, Trihosanthes root and corn stigmas infused with water for 5 hours, then filtered and the filtrate was concentrated on a moderate scale so as to obtain liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the large powder is mixed well with a liquid concentrate, dried and ground into a fine powder; Glibenclamide and a moderate amount of dextrin (dextrin) are added and mixed well with fine powder to prepare granules, which are then filled into capsules. 11. The method of preparation of the drug according to claim 4, comprising the following steps: Remannia root, Pueraria lobate root, Trihosanthes root and corn stigmas infused with water for 5 hours, then filtered and the filtrate was concentrated on a moderate scale so as to obtain liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the large powder is mixed well with a liquid concentrate, dried and ground into a fine powder; Glibenclamide and a moderate amount of dextrin are added and mixed well with fine powder to prepare granules, the granules are then dried, mixed with a moderate amount of magnesium stearate and then pressed into tablets. 12. The method of preparation of the drug according to claim 4, containing the following steps: Remannia root, Pueraria lobate root, Trihosanthes root and corn stigmas infused with water for 5 hours, then filtered and the filtrate was concentrated on a moderate scale so as to obtain liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the large powder is mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide and a moderate amount of dextrin are added and mixed well with a fine powder to prepare granules. 13. The method of preparation of the drug according to claim 4, comprising the following steps: Remannia root, Pueraria lobate root, Trihosanthes root and corn stigmas infused with water for 5 hours and filtered, then the filtrate is concentrated on a moderate scale so as to obtain liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the large powder is mixed well with a liquid concentrate, dried and ground into a fine powder; Glibenclamide is added and mixed well with fine powder, then an equal amount of Polyethylene Glycol 400 (Poly ethylene Glycol-400) and a small amount of glycerin are added, mixed well and pressed into soft capsules. 14. The method of preparation of the drug according to claim 4, comprising the following steps: Remannia root, Pueraria lobate root, Trihosanthes root and corn stigmas infused with water for 5 hours and filtered, then the filtrate is concentrated on a moderate scale so as to obtain liquid concentrate; Astragalus root, Chinese magnolia vine fruits and Dioscorea rhizome are ground into a large powder, and the large powder is mixed well with a liquid concentrate, then dried and ground into a fine powder, Glibenclamide is added and mixed well with a fine powder to prepare the powder.